FMS Fresenius Medical Care AG & Co. KGaA
USHealthcareAs of 2026-07-10 16:00
Why FMS matters now
Fresenius Medical Care AG & Co. KGaA (FMS) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.02 with +0.46% on the session and $12.90B in market capitalization; recent performance reads 1-month +6.74% and YTD -0.97%.
The latest financial table shown here is Q1 2026, with revenue of $4.61B, net income of $117.5M, and EPS of $0.22. Investors can compare that operating picture with valuation signals such as P/E 13.92 and FCF yield 16.3%.
The latest indexable market news headline is "Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $28.00; recent insider activity includes Renkewitsch Olga filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
13.92
PEG
0.17
P/B
0.85
P/S
0.56
EV/EBITDA
5.97
DCF Value
$87.02
FCF Yield
16.3%
Div Yield
3.7%
Margins & Returns
Gross Margin
26.0%
Operating Margin
10.2%
Net Margin
4.9%
ROE
7.2%
ROA
3.0%
ROIC
5.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.61B | $117.5M | $0.22 |
| Q4 2025 | $5.07B | $327.1M | $0.57 |
| FY 2025 | $19.63B | $978.4M | $1.68 |
| Q3 2025 | $4.88B | $274.8M | $0.47 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$28.00
Target (Median)
$28.00
Target Range
$28.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Care Facilities
Country
DE
Exchange
—
Beta
0.81
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.